AL
Allarity Therapeutics, Inc.
ALLR · NASDAQ
$1.04 +0.00% (+$0.00)
1M -27.27%
Market Cap $16.5M
P/E Ratio -
Div. Yield -
ROE 152.77%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
21 /100
Expensive P/S 47.96x
P/B 4.68x
P/E N/A
Growth
100 /100
Growing Book val. growth 73.25%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 107.54%
Net margin 3,575.07%
FCF margin 3,994.78%
Quality
0 /100
Poor ROIC 41.81%
ROE 152.77%
Asset turnover 0.01x
Debt
10 /100
High Debt/Equity 6.30x
Current ratio 1.11x
Int. coverage -10.36x
Stability
76 /100
Stable Beta 0.56x
EPS volatility 9.73%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALLR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas H. Jensen
Employees
8
Headquarters
Tarpon Springs
Upcoming events
13 NOV
Earnings
Upcoming earnings report